Aptevo Therapeutics (NASDAQ:APVO) began dosing subjects in its Phase 1 trial for APVO210, a targeted cytokine immunotherapy.
APVO210 is a modified form of the cytokine, IL-10, that suppresses inflammation without stimulating lymphocytes. Its mechanism of action is expected to reduce toxicities observed in clinical trials of repeated IL-10 administration.
The Phase 1 trial will assess single, followed by multiple ascending doses of APVO210 administered by intravenous infusion either weekly or biweekly for four weeks. Once a clinical dose is established, Aptevo plans to conduct an expansion phase of the trial in patients with psoriasis or ulcerative colitis.
Aptevo expects to report initial dosing and preliminary safety data in third and fourth quarters of 2019, respectively.
